Opthea Limited (OPT), an ASX-listed company, develops and commercialize therapies primarily for eye disease. Opthea's lead asset, sozinibercept (OPT-302), is a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3" in clinical development as a novel therapy for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Wet AMD and DME are leading causes of blindness in the elderly and diabetic populations respectively and are increasing in prevalence worldwide.
ASX Code | OPT |
Website | http://www.opthea.com |
Industry/Sector | Biotechnology |
Market Cap ($M) | 490 |
OPT Share Price | $0.740 |
Day High | $0.788 |
Day Low | $0.740 |
Last Close | $0.740 |
OPT Share Price Movement | - ( No change ) |
There are no dividends for Opthea Limited (OPT). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
---|---|---|---|---|---|
Opthea to Host Key Opinion Leader Event on April 3, 2024 | 19 Mar 2024 11:50AM | $0.630 | $0.740 | $0.625 | risen by 17.46% |
Opthea to Participate in Leerink Global Biopharma Conference | 6 Mar 2024 8:19AM | $0.645 | $0.740 | $0.625 | risen by 14.73% |
Opthea Corporate Presentation - March 2024 | 4 Mar 2024 11:51AM | $0.635 | $0.740 | $0.625 | risen by 16.54% |
See all ASX announcements from Opthea Limited (OPT) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
---|---|---|---|---|---|---|---|
2025F | C2 | -$5.00 | -13.30% | 0.00 | 0.00 | 0.00% | 0.0% |
2024F | C2 | -$5.70 | -87.50% | 0.00 | 0.00 | 0.00% | 0.0% |
2023A | -$214.96 | -$45.80 | 26.70% | 0.00 | 0.00 | 0.00% | 0.0% |
Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | ||
CSL (CSL) | $138,379M | -0.0712 | 0.1072 | 0.1864 | 41.9094 | 37.8519 | 31.9053 | 1.24% | 1.17% | 1.32% |
Clinuvel Pharmaceuticals (CUV) | $711M | 0.4665 | 0.2049 | 0.1566 | 23.9932 | 19.9129 | 17.2171 | 0.35% | 0.49% | 0.56% |
Imugene (IMU) | $768M | 1.3429 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
Opthea (OPT) | $490M | 0.2671 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
Telix Pharmaceuticals (TLX) | $4,167M | -1.3767 | 0.4263 | 1.1667 | 101.9017 | 71.4444 | 32.9744 | 0.00% | 0.00% | 0.00% |
Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
---|---|---|---|---|
Company | 0.00 | 0.00 | -41.60 | 0.00 |
Market | 0.50 | 15.20 | 1.13 | 1.13 |
Sector | 1.35 | 21.40 | 1.86 | 1.17 |
Name | Position | Start Date |
---|---|---|
Dr Jeremy Levin | Non-Executive Chairman, Non-Executive Director | 12 Oct 2020 |
Mr Lawrence Bernard Gozlan | Non-Executive Director | 24 Jul 2020 |
Mr Daniel Spiegelman | Non-Executive Director | 10 Sep 2020 |
Dr Julia Haller | Non-Executive Director | 1 Jun 2021 |
Dr Susan Orr | Non-Executive Director | 21 Apr 2022 |
Mr Quinton Oswald | Non-Executive Director | 21 Apr 2022 |
Mr Anshul Thakral | Non-Executive Director | 7 Jun 2023 |
Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
---|---|---|---|---|---|---|
1 Mar 2024 | BALDWIN, Megan | Sell | Indirect Shares | 3,012,277 | $0.550 | $1,656,752.350 |
1 Mar 2024 | BALDWIN, Megan | Sell | Direct Shares | 987,723 | $0.550 | $543,247.650 |
28 Nov 2022 | BALDWIN, Megan | Buy | Indirect Shares | 355,901 | $0.480 | $170,832.480 |
See all changes in directors' interest & trades for Opthea Limited (OPT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
Name | Position |
---|---|
Judith Robertson | Chief Commercial Officer |
Frederic Guerard | Chief Executive Officer |
Timothy Morris | Chief Financial Officer |
Joel Naor | Chief Medical Officer |
Karen Adams | Company Secretary,Vice President of Finance |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Opthea Limited (OPT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
Holding | Name |
---|---|
93,246,599 (20%) | Regal Funds Management Pty Limited |
33,322,088 (7.10%) | USB Group AG |
31,627,844 (6.80%) | Bakers Brothers Life Sciences LP |
23,425,608 (5%) | Bank of America Corporation and its related bodies corporate |
Date | Event |
---|---|
27 February 2025 | Report (Interim) |
26 September 2024 | Report (Annual) |
29 August 2024 | Report (Prelim) |
Opthea Limited's (OPT) current share price is $0.74. This constitutes a price movement of 18.40% when compared to the share price 7 days ago and is 0% below OPT's 12-month high of $0.74 per share. Prices are delayed by at least 20 minutes.
Relative to the previous close share price of $0.74, Opthea Limited's (OPT) current share price of $0.74 constitutes a movement of or 0%. Opthea Limited's (OPT) share price movement is 18.40% when compared to 7 days ago and is 0% below OPT's 52-week high of $0.74.
Opthea Limited's (OPT) 52-week high is $0.74 which was reached on 4 Apr 2023. Relative to this, OPT's current share price of $0.74 constitutes a or 0% drop since that high of $0.74 per OPT share.
Opthea Limited's (OPT) 52-week low is $0.32 which was reached on 2 Oct 2023. Relative to this, OPT's current share price of $0.74 constitutes a $0.43 or 134.92% gain since that low of $0.32 per OPT share.
Over the last 12 months, Opthea Limited (OPT) has a daily average trading volume of 412,902 OPT shares per day.
Opthea Limited (OPT) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for OPT is a ratio that tells you the percentage of Opthea Limited's (OPT) share price that it pays out in dividends each year.
Opthea Limited (OPT) has a franking level of 0%. Franking represents the tax Opthea Limited (OPT) has already paid on any profit it distributes to shareholders as a dividend.
Opthea Limited (OPT) will release its next Annual Report on 26 September 2024. Opthea Limited's (OPT) last annual report was released on 28 Sep 2023. Click here to view Opthea Limited's (OPT) last annual report.
Opthea Limited (OPT) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Sonic Healthcare Limited (SHL).
The price-to-earnings (P/E) ratio for Opthea Limited (OPT) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Opthea Limited's (OPT) share price to its earnings per OPT share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.